Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nectar Lifesciences Ltd. ( (IN:NECLIFE) ) has shared an announcement.
Nectar Lifesciences Ltd. has notified the stock exchanges that it received a quarterly compliance certificate from its registrar and share transfer agent, KFin Technologies Ltd., under Regulation 74(5) of SEBI’s Depositories and Participants Regulations, 2018. KFin confirmed that all securities received for dematerialisation during the quarter ended March 31, 2026, were duly processed, listed in line with existing securities, and that corresponding physical certificates were cancelled and records updated within prescribed timelines, underscoring the company’s adherence to regulatory requirements in handling its listed shares.
This regulatory confirmation provides assurance to investors and market participants that Nectar Lifesciences is maintaining proper dematerialisation practices and accurate shareholding records in coordination with depositories and stock exchanges. The filing reinforces the company’s commitment to securities market compliance, which is important for transparency, investor confidence, and smooth trading of its equity on the NSE and BSE.
More about Nectar Lifesciences Ltd.
Nectar Lifesciences Ltd. is an India-based pharmaceutical company operating in the life sciences sector, with corporate offices in Chandigarh and manufacturing and registered facilities in Punjab. The company’s shares are listed on both the National Stock Exchange of India and BSE, reflecting its presence in the Indian capital markets.
Average Trading Volume: 60,437
Technical Sentiment Signal: Sell
Current Market Cap: 2.24B INR
See more data about NECLIFE stock on TipRanks’ Stock Analysis page.